Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
20.07%
operating margin TTM
25.91%
revenue TTM
72.33 Million
revenue per share TTM
0.9$
valuation ratios | |
|---|---|
| pe ratio | 10.44 |
| peg ratio | -0.01 |
| price to book ratio | 2.38 |
| price to sales ratio | 2.12 |
| enterprise value multiple | 8.72 |
| price fair value | 2.38 |
profitability ratios | |
|---|---|
| gross profit margin | 69.97% |
| operating profit margin | 25.91% |
| pretax profit margin | 25.22% |
| net profit margin | 20.07% |
| return on assets | 14.98% |
| return on equity | 28.1% |
| return on capital employed | 26.41% |
liquidity ratios | |
|---|---|
| current ratio | 3.15 |
| quick ratio | 2.04 |
| cash ratio | 1.52 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 484.87 |
| operating cycle | 498.92 |
| days of payables outstanding | 68.18 |
| cash conversion cycle | 430.74 |
| receivables turnover | 25.99 |
| payables turnover | 5.35 |
| inventory turnover | 0.75 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.08 |
| debt equity ratio | 0.13 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.11 |
| interest coverage | 12.86 |
| cash flow to debt ratio | 1.78 |
cash flow ratios | |
|---|---|
| free cash flow per share | 0.18 |
| cash per share | 0.65 |
| operating cash flow per share | 0.19 |
| free cash flow operating cash flow ratio | 0.97 |
| cash flow coverage ratios | 1.78 |
| short term coverage ratios | 10.53 |
| capital expenditure coverage ratio | 33.16 |
Frequently Asked Questions
When was the last time Protalix BioTherapeutics, Inc. (AMEX:PLX) reported earnings?
Protalix BioTherapeutics, Inc. (PLX) published its most recent earnings results on 13-05-2026.
What is Protalix BioTherapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Protalix BioTherapeutics, Inc. (AMEX:PLX)'s trailing twelve months ROE is 28.1%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Protalix BioTherapeutics, Inc. (PLX) currently has a ROA of 14.98%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did PLX's net profit margin stand at?
PLX reported a profit margin of 20.07% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is PLX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 3.15 in the most recent quarter. The quick ratio stood at 2.04, with a Debt/Eq ratio of 0.13.